3,5,3'-Triiodothyronine Sulfate As Thyromimetic Agent And Pharmaceutical Formulations Thereof

• US 20130146502A1
• Filed: 01/31/2013
• Published: 06/13/2013
• Est. Priority Date: 11/13/2002
• Status: Active Grant

• Current Assignee: Bracco SPA
• Original Assignee: Bracco SPA
• Inventors: MAISANO, Federico
• Granted Patent: US 9,044,441 B2
• Time in Patent Office: Days
• US Class Current: 206/568
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: G01N 21/76 Chemiluminescence; Bioluminescence
• CPC Class Codes: G01N 33/561 Immunoelectrophoresis
• CPC Class Codes: G01N 33/78 Thyroid gland hormones , e.g. T3, T4, TBH, TBG or their receptors

Abstract

The invention regards the use of triiodothyronine sulfate, commonly named T₃S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T₃), as such or in association with thyroxine (T₄), and pharmaceutical formulations for oral administration thereof.

Claims

1-15. -15. (canceled)

16. A non radioactive immunoassay for T₃S quantitation comprising a non radioactive T₃S-conjugate.

17. The immunoassay of claim 16 wherein the non radioactive conjugate is T₃S-biotin.

18. The immunoassay of claim 17 wherein the immunoassay is a competitive ELISA.

19. The immunoassay of claim 16 wherein the non radioactive conjugate is a T₃S conjugate comprising the compound of Formula I as a Lanthanide chelating agent

20. The immunoassay of claim 16 comprising a DELFIA®

assay.

21. A kit comprising a container for a non radioactive immunoassay according to claim 16 and a container for a solid oral dosage composition comprising T₃S as the active principle, in a quantity ranging from 1 to 1000 μ

g and further comprising diluents, glidants or lubricants and disintegrants.

22-27. -27. (canceled)